Omega-3-carboxylic acids/Dapagliflozin Propanediol Monohydrate

奥米加-3羧酸/达格列净丙二醇-水合物

Report date: 2022/01/14 13:23:58

Base Information

Drug NameOmega-3-carboxylic acids/Dapagliflozin Propanediol Monohydrate
Drug Alias Name达格列净丙二醇-水合物/奥米加-3羧酸Dapagliflozin Propanediol Monohydrate/Omega-3-carboxylic acids
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionLipid modulatorsSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2Lipid
Therapy Area/IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Dapagliflozin Propanediol MonohydrateOmega-3-carboxylic acids
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A